ProtoKinetix, Incorporated
PKTX
Other OTC0.01
USD
- -
- -
CIK
0001128189
ISIN
US7437221002
CUSIP
743722100
Return %
Stock
S&P500
1Y
-24.71
19.01
3Y
-75.38
65.48
5Y
-95.08
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Richard Guzzetta
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 109 W Main St Dalton OH United States of America 45750
- IPO Date
- Apr 22, 2002
- CIK
- 0001128189
- Website
- protokinetix.com
- Similar Companies
- Business
- ProtoKinetix, Incorporated is a clinical-stage biomedical biotechnology company specializing in the research and development of proprietary anti-aging and anti-freeze glycoproteins (AAGP® and AFGPs) aimed at improving cell survival and health therapies. The company’s core products include the patented AAGP® molecule, which is designed for applications across targeted healthcare solutions such as ophthalmology, dermatology, transplant support, and biomanufacturing. Key product developments include formulations of AAGP® for ocular conditions like dry eye disease and age-related macular degeneration, supported by ongoing preclinical and Phase 1 clinical trials. ProtoKinetix actively collaborates with global pharmaceutical partners and contract research organizations, such as IQVIA and Catalent, to accelerate clinical development and commercialization of topical and cellular therapies using AAGP®. Incorporated in 1999, the company is headquartered in Dalton, Ohio, and operates primarily in the United States with research tie-ins at institutions like the University of Alberta and the University of British Columbia. Recent strategic developments include the resumption and advancement of Phase 1 and Phase 1b clinical trials for AAGP®-treated islet cells targeting Type 1 diabetes, collaboration with IQVIA to expedite ocular clinical trials, and the selection of two topical drug formulations for dry eye disease treatment advancing into preclinical efficacy testing and FDA regulatory preparation. ProtoKinetix also announced partnerships with multinational firms to develop and commercialize AAGP®-based ophthalmic drugs, marking a significant move towards market expansion in the dry eye disease sector, valued in the billions. The company remains focused on leveraging its AAGP® technology platform for regenerative medicine and biopharmaceutical applications while maintaining a debt-free balance sheet and pursuing additional research partnerships and funding to support its product pipeline and commercialization efforts. ProtoKinetix operates within the healthcare biotechnology industry, targeting markets that include pharmaceutical, ophthalmic, dermatological, transplant, and biomanufacturing sectors. Its research efforts focus on enhancing cell viability and therapeutic efficacy with a growing product pipeline including PKX-001 and other AAGP® formulations. The company's latest major operational shifts involve clinical progress in immune and cell survival therapies, formulation advancements for topical drugs, and strategic alliances to support both regulatory approval processes and market-ready product development. Clarence Edward Smith serves as Chairman, President, and CEO, leading the company’s forward-looking initiatives in the U.S. biotechnology sector.
ProtoKinetix (OTCMKTS:PKTX) Shares Pass Below 50-Day Moving Average – Here’s What Happened
ProtoKinetix (OTCMKTS:PKTX) Shares Pass Below 50-Day Moving Average – Here’s What Happened
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions